^
Association details:
| Biomarker: | FLT3 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | XY0206 (FLT3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2908 A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Published date:
11/02/2023
Excerpt:
XY0206 is a novel FLT3 inhibitor that showed a good safety profile, a potent anti-leukemic activity and improved efficacy in patients with FLT3mut+ R/R AML.
